Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

"A dynamic and versatile pharmaceutical company with regional horizons in Latin America." "Axon Pharma is an independent multinational pharmaceutical company built on high-standards science and ...

Dizal has submitted an application to the US FDA for sunvozertinib, an oral EGFR inhibitor for advanced NSCLC with EGFR exon 20 insertion mutations, aimed at patients after platinum-based chemotherapy ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

A review has found that complexities and inefficiencies within the UK’s health data infrastructure are hindering the ...

Italian pharma major Recordati saw its shares dip 3.75% to 50.10 euros this morning, despite posting a set of strong financial results. Consolidated net revenue for the first nine months of 2024 was 1 ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...